Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SITC 2021 | COVID-19 prophylaxis: bolstering boosters

Samir Parekh • 10 Nov 2021
SITC 2021
Multiple Myeloma Antibodies CAR-T Daratumumab

Samir N. Parekh, MD, Icahn School of Medicine at Mount Sinai, New York City, NY, discusses the potential of prophylactic strategies against COVID-19 in patients with hematological malignancy, specifically commenting on how such strategies could complement booster vaccines. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Samir Parekh

Making CAR T-cell therapy for multiple myeloma available globally: what needs to be done?
0:59
Making CAR T-cell therapy for multiple myeloma available globally: what needs to be done?
Samir Parekh • 6 Dec 2025
Earlier use of cilta-cel is associated with better immune fitness in multiple myeloma: CARTITUDE-4
4:50
Earlier use of cilta-cel is associated with better immune fitness in multiple myeloma: CARTITUDE-4
Samir Parekh • 6 Dec 2025
The role of the immune system as a mechanism of resistance to T-cell engagers in multiple myeloma
5:15
The role of the immune system as a mechanism of resistance to T-cell engagers in multiple myeloma
Samir Parekh • 19 Sep 2025
The potential of iberdomide to enhance CAR T-cell expansion and functionality in multiple myeloma
1:13
The potential of iberdomide to enhance CAR T-cell expansion and functionality in multiple myeloma
Samir Parekh • 19 Sep 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Samir Parekh • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Samir Parekh • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Samir Parekh • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Samir Parekh • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals